Share >  
Share
Share on Tumblr

Actavis

News »

   latest by relevance
US court bans Sun Pharma from selling generic Eloxatin
Apr 26, 2010 at 09:04 | Source: CNBC-TV18
The US district court has asked Sun Pharma to stop selling its generic version of Eloxatin from June 30. CNBC-TV18s Ekta Batra reports
Ratiopharm fields decisive takeover bids
Feb 07, 2010 at 11:17 | Source: Reuters
Teva and Actavis have placed make-or-break bids for German peer Ratiopharm but drug major Pfizer is expected to also be a contender.
Glenmark posts cons revenue growth of 29.78%
Jul 28, 2008 at 13:57
Glenmark posts consolidated revenue growth of 29.78% and Net profit growth of 101.88 % for Q1 FY09. Consolidated revenue at Rs. 4664.50 Mn and Net Profit at Rs. 1153.76 Mn
Glenmark signs agreement with Actavis
Jul 02, 2008 at 15:20
Glenmark establishes a new company in Poland and acquires a product portfolio of 7 established brands. The acquisition of the products from these two different companies for an undisclosed sum will provide Glenmark its first access to the growing Polish market, the largest pharmaceutical market in Central & East Europe.
Domestic mkt growing at 18% annually: IPCA Labs
Sep 13, 2007 at 15:52
AK Jain, ED at IPCA Labs informs that domestic market growing at 18% annually, and the company will be looking maintaining the growth. He adds that the basket of API will go to 75 APIs in the next 3-4 years.
Orchid forays into non-antibiotic generic formulations seg
Jun 15, 2007 at 14:10
Orchid forays into the non-antibiotic generic formulations segment. Receives tentative approval from US FDA for Terbinafine HCL Tablets ANDA

Videos »
US court bans Sun Pharma from selling generic Eloxatin
Domestic mkt growing at 18% annually: IPCA Labs
Dr Reddy's bows out of race for Mercks generics biz
more »

Photos »

  /  
News across the web »
Thursday’s top gaining and declining stocks
CHICAGO (MarketWatch) — Shares of the following companies made notable moves on Thursday: Gainers Carter’s Inc. (NYSE:CRI)   rose 5.6% after the retailer’s first-quarter profit topped estimate...
Apr 26, 2012 at 21:12 | Source: Market Watch
Watson buying generic drugmaker Actavis for $5.6B
Watson Pharmaceuticals Inc. is buying another generic drugmaker, Switzerland's Actavis Group, for about $5.6 billion in a move that will make Watson in the world's third-biggest generi...
Apr 26, 2012 at 06:00 | Source: Business Week
Watson to Buy Actavis for $5.6 Billion in Generics Deal
By Alex Nussbaum and Naomi Kresge on April 25, 2012 Watson Pharmaceuticals Inc. (WPI) (WPI), maker of the generic version of Lipitor cholesterol pills, agreed to buy closely held drugmaker Actavis Gro...
Apr 26, 2012 at 02:00 | Source: Business Week
U.S. stock index futures signal gains for equities
LONDON: U.S. stock index futures pointed to a stronger open for equities on Wall Street on Wednesday, with futures for the S&P 500, the Dow Jones and the Nasdaq 100 rising 0.5 to 1.8 percent. * Apple...
Apr 25, 2012 at 16:17 | Source: Economic Times
U.S. stock indexes rise on earnings
NEW YORK (MarketWatch) — U.S. stocks solidified Tuesday gains as investors considered another round of economic data and a slew of corporate earnings, including upbeat results from 3M Co. “World ...
Apr 24, 2012 at 21:42 | Source: Market Watch
more »
Interact & exchange stock tips & market info »

Web Messenger

Platinum Member

107998 Followers

News Now  

Source:Business Week - Watson Pharmaceuticals Inc. is buying another g...

1.02 PM Apr 26th

Web Messenger

Platinum Member

107998 Followers

News Now  

Source:Forbes - Following a notable pick-up in call volume on the gen...

10.00 AM Apr 5th

Web Messenger

Platinum Member

107998 Followers

News Now  

Source:Wall Street Journal - By Eyk Henning Of DOW JONES NEWSWIRES FRA...

1.01 PM Mar 22nd

Related News »
Actavis receives FDA approval for Ropinirole ER Tablets
Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL.
May 19, 2012 at 06:38 | Source: News-Medical.Net
Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
Wells Fargo upgraded Watson Pharmaceuticals (NYSE: WPI) from Market Perform to Outperform, raising price target range from $75-79 to $84-90. Analyst, Michael Tong, said, "We have had a positive outlook on WPI's proposed Actavis acquisition. However, we ...
May 24, 2012 at 11:18 | Source: StreetInsider.com
Watson Announces Formation of Global Integration Management Office to Support Pending Actavis Acquisition
PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (WPI) today announced that it has created a Global Integration Management Office, reporting directly to Paul M. Bisaro, President and Chief Executive Officer, and ...
May 28, 2012 at 06:49 | Source: Yahoo Finance
Watson Pharma rises on Wells Fargo analyst upgrade
THE BIG PICTURE: Watson agreed to buy its rival, Actavis, on April 25 for $5.6 billion. Actavis is based in Switzerland, and Watson said the deal will expand its business in Russia and Central and Eastern Europe. It will also make Watson the ...
May 28, 2012 at 03:14 | Source: Yahoo Finance
FDA approves Actavis' generic of GSK's Requip XL
Want to see more news summaries? Sign up for AHIP Solutions SmartBrief AHIP Solutions SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news ...
May 22, 2012 at 15:10 | Source: SmartBrief
Actavis Launches First Generic Equivalent Of Requip® XL (Ropinirole Extended-Release Tablets)
MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic ...
May 18, 2012 at 11:04 | Source: TheStreet.com
BofA Merrill Names New Healthcare Banking Head
That followed a stint at J.P. Morgan Chase & Co. He joins a healthcare franchise at BofA that already has some momentum, having advised Watson Pharmaceuticals on its $5.9 billion agreement last month to buy Swiss generic-drug company Actavis ...
May 21, 2012 at 14:21 | Source: Wall Street Journal
QRxPharma Granted Additional US Patent on MoxDuo®
The Company is partnered with Actavis, Inc. to commercialise MoxDuo IR in the US acute pain market, with product launch anticipated in 3Q, CY2012. QRxPharma may co-promote its products in the US and plans to seek strategic partnerships for ...
May 23, 2012 at 11:34 | Source: Marketwatch
Staff cluck their way into skydive
North Devon Hospice and Skydive UK have teamed up to offer one lucky person the chance to win a free parachute jump in July and the feathered team from Actavis, in Barnstaple, will be taking part on the same day. People can join them by entering the ...
May 18, 2012 at 05:56 | Source: Torquay Herald Express
United States, ex rel v. Actavis Mid-Atlantic, et al
Virginia joined the federal government and other states Thursday in accusing Healthpoint Ltd. of costing Medicaid agencies more than $500 million by falsely claiming its bedsore ointment Xenaderm was eligible for reimbursement coverage.
May 18, 2012 at 21:55 | Source: site.law360.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window